title: Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
abstract: We found no evidence for an oncogenic risk or poorer survival associated with using RAL compared with control groups.
journal: HIV Medicine